Company Profile
Entera Bio Stock Price, News & Analysis
- Ticker:
- ENTX
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- Israel and listed in the U
Stock performance
2.82 USD (+0.36%)
Close
Last updated: August 6, 2026
61.5M USD
Market cap
Why the stock is moving
The latest monitored company update is “Entera Announces Second Quarter 2026 Financial Results and Business Updates.” The corresponding closing-price reaction is not yet available.
Company overview
Oral Peptide Delivery
Entera Bio develops oral formulations of peptides and proteins that have traditionally required injection. Its proprietary N-Tab platform is designed to improve intestinal absorption in a convenient tablet form.
EB613 Osteoporosis Program
EB613 is an oral parathyroid-hormone peptide candidate intended to provide anabolic, bone-building treatment for postmenopausal osteoporosis without daily injections.
EB612 Hypoparathyroidism Program
EB612 is an oral long-acting PTH replacement candidate for hypoparathyroidism. It is being developed through an equal partnership with OPKO Health.
EB618 Metabolic Program
EB618 is an oral oxyntomodulin candidate designed for dual GLP-1 and glucagon receptor activity in metabolic and fibrotic diseases, extending the platform beyond replacement therapies.
Platform Business Model
Entera uses N-Tab both for internally controlled candidates and partnered programs, allowing the same delivery technology to support multiple peptide classes and therapeutic areas.
Future catalysts
FDA feedback on the submitted Phase 3 protocol for EB613.
IND submission for EB612 in late 2026.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Entera Bio (ENTX)?
Entera Bio (ENTX) most recently closed at 2.82 USD, a +0.36% move versus the previous session.
What is the market cap of Entera Bio (ENTX)?
Entera Bio currently has a market capitalization of 61.5M USD on BioPharmSignal.
What does Entera Bio do?
Oral Peptide Delivery Entera Bio develops oral formulations of peptides and proteins that have traditionally required injection. Its proprietary N-Tab platform is designed to improve intestinal absorption in a convenient tablet form. EB613 Osteoporosis Program EB613 is an oral parathyroid-hormone peptide candidate intended to provide anabolic, bone-building...
On which exchange is ENTX stock listed?
Entera Bio (ENTX) is associated with NASDAQ, Israel and listed in the U, Biopharma.
What is GLP-1?
EB618 Metabolic Program EB618 is an oral oxyntomodulin candidate designed for dual GLP-1 and glucagon receptor activity in metabolic and fibrotic diseases, extending the platform beyond replacement therapies.
Which conditions is Entera Bio targeting with GLP-1?
Entera Bio is associated with metabolic disease based on its company overview and current catalyst commentary.
How does Entera Bio describe recent progress with GLP-1?
FDA feedback on the submitted Phase 3 protocol for EB613. IND submission for EB612 in late 2026.
What is Oral?
Oral Peptide Delivery Entera Bio develops oral formulations of peptides and proteins that have traditionally required injection.